ADMA Biologics, Inc. is a commercial-stage biopharmaceutical company focused on manufacturing, marketing, and developing specialty plasma-derived therapies for immunodeficient patients. Its main product, ASCENIV, serves as an immune globulin treatment for primary humoral immunodeficiency, while BIVIGAM functions as an intravenous immune globulin for similar groups. The company also offers Nabi-HB, a hepatitis B immune globulin.
Vertical integration sets the business apart, with its own plasma collection centers and FDA-approved manufacturing sites in Boca Raton, Florida. This control over sourcing and production helps manage supply, quality, and costs effectively. I find investors tend to follow ADMA closely for ASCENIV's growth path, expanding gross margins, and steady capital allocation approach. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
In the trailing 30-day stretch, ADMA shares moved from a closing price near $10.73 to roughly $13.68, for a gain of about 27%. A large part of that shift occurred right after the third-quarter earnings release, when the stock rose more than 25% on heavy volume.
The longer trend looks even stronger. Over the last quarter of about three months, the stock advanced from around $9.40–$9.50 in mid-August to current levels, marking an increase of approximately 44%. This reflects improving sentiment after a tougher first half of the year, with renewed focus on commercial progress and profitability.
The main driver came from ADMA's third-quarter 2026 results, released in early November. Total revenue hit $141.1 million, up 5% year over year and 13% sequentially, beating estimates by about $3 million. GAAP earnings per share of $0.22 also exceeded expectations.
ASCENIV stood out with $124.7 million in revenue, rising 31% year over year and 21% sequentially. Management pointed to broader physician adoption, new patient starts, and higher utilization. Gross margin reached 71%, up from 56% a year earlier, thanks to a favorable product mix and better manufacturing yields. I’m watching this closely as the company raised its full-year 2026 outlook, lifting minimum adjusted EBITDA guidance to at least $275 million from $265 million and adjusted net income to at least $180 million from $170 million, while keeping revenue guidance at least $530 million. Constructive FDA feedback on the SG-001 pre-IND package also added interest, with that candidate holding an estimated $300–500 million annual revenue potential.
The quarterly move ties into a broader recovery story. After challenges in the first half of 2026, confidence has grown around accelerating ASCENIV demand, margin expansion, and stronger profitability. Higher gross margins and operating leverage turned revenue growth into quicker earnings growth, while share repurchases of 16.5 million shares year-to-date helped reduce the share count and support per-share metrics.
Pipeline work on SG-001, supported by the proprietary ADMAlytics AI platform, adds a longer-term angle. Still, the period showed some mixed signals, with BIVIGAM revenue falling to $15.4 million amid pricing pressure in the standard immunoglobulin market—a point the company has noted while emphasizing ASCENIV's more consistent growth.
Looking ahead, durability of ASCENIV demand and whether utilization trends hold into 2027 stand out as key items. Updates to full-year guidance, fourth-quarter results, and comments on the competitive immunoglobulin market will draw attention, especially with signs of stabilization noted for BIVIGAM. Pipeline developments on SG-001, including a planned IND submission and potential study timelines, offer a longer-term catalyst. Broader factors like reimbursement trends, plasma supply, and sector sentiment could also play a role. As with any single-stock holding, these elements involve risk, so personal research and risk tolerance matter here.
I've found Tickeron's AI Daily Buy/Sell Signals helpful for spotting patterns across holdings like this one, as it provides a data-driven layer to supplement earnings analysis and valuation checks without replacing core fundamentals review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ADMA's Aroon Indicator triggered a bullish signal on November 16, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 256 similar instances where the Aroon Indicator showed a similar pattern. In 212 of the 256 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on ADMA as a result. In 70 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for ADMA just turned positive on November 05, 2026. Looking at past instances where ADMA's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.
Following a +3.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in 245 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The 10-day RSI Indicator for ADMA moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 27 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
ADMA broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ADMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.985) is normal, around the industry mean (3.586). P/E Ratio (17.681) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.170) is also within normal values, averaging (440.869).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics
Industry Biotechnology